Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
The Emerging Landscape of Urological Cancers: Proven Concepts, Novel Insights
share announcement

The Emerging Landscape of Urological Cancers: Proven Concepts, Novel Insights

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 January 2025) | Viewed by 2371

Special Issue Editors

Dr. Christian P. Meyer

E-Mail Website
Guest Editor
Department of Urology, Ruhr-University Bochum, Campus OWL Herford, Herford, Germany
Interests: renal; testicular; bladder cancer
Dr. Raisa S. Pompe

E-Mail Website
Guest Editor
Department of Urology, Ruhr-University Bochum, Campus OWL Herford, Herford, Germany
Interests: prostate
Dr. Quoc-Dien Trinh

E-Mail Website
Guest Editor
Department of Urology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Interests: prostate cancer; health services research; equity

Special Issue Information

Dear Colleagues,

Uro-Oncology continues to be one of the most exciting fields in all of medicine. With more than 2 million new diagnoses per year and an expected continued surge over the next decade, especially in developing countries, we will face a magnitude of challenges in diagnostics, therapies and prevention.

Organ-confined, urological cancers can be treated by local treatments like (minimally-invasive) surgery or radiation with all their potential side-effects. Once spread, prognosis of most urological cancer entities remains poor. However, the treatment landscape is rapidly changing and we are continuously learning to integrate different treatment options for a more tailored and personalized approach for our patients. This Special Issue aims to 1. give an overview of recent treatment developments in urological cancer therapies, including innovative operative techniques as well as novel systemic approaches using immuno-, chemo- and other targeted or radioligand therapies and 2. provide the opportunity to display cutting-edge and thought-provoking concepts in this challenging setting.

In this Special Issue, original research articles and reviews on kidney, urothelial, prostate, penile and testicular cancer are welcome. We very much look forward to receiving your contributions.

Dr. Christian P. Meyer
Dr. Raisa S. Pompe
Dr. Quoc-Dien Trinh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urological cancer
  • genito-urinary cancer
  • novel therapies
  • prostate cancer
  • kidney cancer
  • bladder cancer
  • penile cancer
  • testicular cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 763 KiB  
Article
The Effect of Audio and Audiovisual Distraction on Pain and Anxiety in Patients Receiving Outpatient Perineal Prostate Biopsies: A Prospective Randomized Controlled Study
by Julia Carola Kaulfuss, Nicolas Hertzsprung, Henning Plage, Benedikt Gerdes, Sarah Weinberger, Thorsten Schlomm and Maximilian Reimann
Cancers 2025, 17(6), 959; https://doi.org/10.3390/cancers17060959 - 12 Mar 2025
Viewed by 435
Abstract
Background/Objectives: Audio and audiovisual distraction can be effective additive tools to reduce anxiety and pain in patients receiving outpatient procedures (OP). Audiovisual distraction tools already showed positive effects on pain perception in some urological procedures. To identify the effects of audio and audiovisual [...] Read more.
Background/Objectives: Audio and audiovisual distraction can be effective additive tools to reduce anxiety and pain in patients receiving outpatient procedures (OP). Audiovisual distraction tools already showed positive effects on pain perception in some urological procedures. To identify the effects of audio and audiovisual distraction on pain and anxiety in patients receiving perineal prostate biopsy (PPB), we performed a prospective randomized controlled study. Methods: We recruited 168 male patients undergoing PPB which were randomized into three groups: a control group (CG), an audio distraction group (ADG) and an audiovisual distraction group (AVDG). The CG received no intervention, while the ADG received audio distraction and the AVDG received audiovisual distraction while PPB was performed. The primary endpoint was pain perception, measured in the Numeric Rating Scale (NRS) and Visual Analogue Scale (VAS). Secondary endpoints were subjective and objective procedure time (SPT/OPT), heart rate, blood pressure, cortisol blood levels and scores in the State-Trait Anxiety Inventory (STAI) questionnaire. Results: Demographics of each group were similar (CG = mean age (a) = 69.5; ADG a = 67 years; AVDG a = 67). We did not find any significant difference regarding our primary endpoint, pain perception (p = 0.384). In contrast, we examined a highly significant difference between SPT and OPT, comparing AVDG to CG (p < 0.001) and AVDG to ADG (p < 0.001), but not for ADG to CG (p = 0.348). There was no significant difference in the secondary endpoints, heart rate, blood pressure, STAI scores and willingness to repeat the procedure. Conclusions: Our study shows that audiovisual distraction can significantly shorten SPT for patients receiving PPB, which may represent their comfort throughout the procedure. To accelerate the wider implementation of audiovisual distraction as a cost-efficient tool in outpatient urological procedures, further studies should examine its effect on different OPs with a more heterogeneous patient group. Full article
(This article belongs to the Special Issue The Emerging Landscape of Urological Cancers: Proven Concepts, Novel Insights)
►▼ Show Figures

Figure 1

12 pages, 391 KiB  
Article
Assessment of Different Castration Resistance Definitions and Staging Modalities in Metastatic Castration-Resistant Prostate Cancer
by Mike Wenzel, Benedikt Hoeh, Clara Humke, Carolin Siech, Cristina Cano Garcia, Georg Salomon, Tobias Maurer, Markus Graefen, Simon Bernatz, Andreas Michael Bucher, Luis Kluth, Felix K. H. Chun and Philipp Mandel
Cancers 2024, 16(20), 3506; https://doi.org/10.3390/cancers16203506 - 17 Oct 2024
Viewed by 1383
Abstract
Background/Objectives: Progression to metastatic castration-resistant prostate cancer (mCRPC) is defined either biochemically, radiographically or both. Moreover, staging for mCRPC can be performed either conventionally or with molecular imaging such as prostate-specific membrane antigen computer tomography (PSMA-PET/CT). Methods: We relied on the [...] Read more.
Background/Objectives: Progression to metastatic castration-resistant prostate cancer (mCRPC) is defined either biochemically, radiographically or both. Moreover, staging for mCRPC can be performed either conventionally or with molecular imaging such as prostate-specific membrane antigen computer tomography (PSMA-PET/CT). Methods: We relied on the Frankfurt Metastatic Cancer Database of the Prostate (FRAMCAP) database to compare progression-free (PFS) and overall survival (OS) outcomes regarding the cause of castration resistance and the staging modality used. Results: Overall, 35% progressed to mCRPC biochemically vs. 23% radiographically vs. 42% biochemically + radiographically. The PSA nadir in mHSPC (1.4 vs. 0.4 vs. 0.8 ng/mL) and PSA level at mCRPC progression (15 vs. 2 vs. 21 ng/mL, both p ≤ 0.01) were significantly higher for biochemical vs. radiographic vs. both progressed patients. In PFS and OS analyses, no significant differences were observed among all three compared groups. In the comparison of the staging used for progression to mCRPC, 67% received conventional vs. 33% PSMA-PET/CT, with higher metastatic burden in mHSPC and osseous lesions in mCRPC for conventionally staged patients (both p < 0.01). In PFS (15.3 vs. 10.1 months, hazard ratio [HR]: 0.75) and OS analyses (52.6 vs. 34.3 months, HR: 0.61, both p < 0.05), PSMA-PET/CT harbored better prognosis; however, this did not hold after multivariable adjustment. Similar results were observed for further analyses in second- and third-line mCRPC or patients with a PSA level of ≥2 ng/mL. Conclusions: The cause of progression to mCRPC seems not to influence cancer-control outcomes, despite important baseline tumor characteristic differences. The PSMA-PET/CT staging modality might be associated with better PFS and OS outcomes, possibly due to its more sensitive detection of progression or new metastatic lesions. Full article
(This article belongs to the Special Issue The Emerging Landscape of Urological Cancers: Proven Concepts, Novel Insights)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop